DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for auditory system disease — screening already-approved drugs against its 32-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAuditory system disease maps to a 32-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for auditory system disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
aspartate beta-hydroxylase (ASPH) — ASPH is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet akgdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9FVU · 1.7 Å · ligand 2-OXOGLUTARIC ACID (AKG). Experimental structure, not a prediction.
What the evidence adds up to
The 1973 handbook describes the clinical role of audiometry in diagnosing hearing loss from causes such as otitis media, tumours, otosclerosis, Meniere disease, syphilis, and presbycusis, and it includes presurgical and postsurgical audiometric findings. No drug treatments are evaluated in that text. The 1979 discussion similarly lists common auditory system diseases and states that unsolved problems require continued research, but it provides no drug efficacy data, no response rates, and no survival figures.
The 2024 editorial notes that most therapeutic drugs are given orally or by injection but that the inner ear’s blood labyrinth barriers often prevent these routes from reaching the target. Local intratympanic injection is considered, but the inner ear is surrounded by bone and has its own membrane barrier; drilling a hole can cause mechanical damage, and the inner ear volume is very small, so drugs must be administered slowly over a long period. The editorial mentions that intratympanic steroid administration is currently used in clinical practice and that two articles in the collection attempt to improve age-related hearing loss or presbycusis, but it gives no numerical outcomes, no sample sizes, and no response rates for any intervention.
The editorial also raises a specific missing piece: because the inner ear size differs between humans and other animals, it is questionable whether nonclinical study results can be applied to humans. Pharmacokinetics in catheterised piglets were evaluated using fluorescent dyes, but no human pharmacokinetic data are reported. What is still missing is a delivery system that can reliably penetrate the inner ear barriers without mechanical damage, a validated animal model that translates to human inner ear dimensions, and any controlled trial showing that a drug delivered by these novel systems improves hearing outcomes in patients.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Pediatrics and Adolescent Medicine · 1973 · 134 citations
Handbook of Clinical Audiology.
AbstractThis comprehensive handbook is devoted to the clinical aspects of auditory disorders, to the differential diagnosis of hearing problems of all kinds, and to the treatment of those problems so far as they lie within the province of the audiologist. It is a readable book with considerable relevance for otolaryngologists, neuro-otologists, pediatricians, pediatric scientists, general practitioners, internists, neurologists, and neurosurgeons. The physician who relies upon audiometric test findings in the treatment of his patients will be interested in the chapter on calibration of equipment. Also of interest will be the chapter on otological correlates of audiology. Many causes of hearing loss are discussed together with the audiograms of patients with confirmed diagnoses of such disorders as otitis media, tumors, otosclerosis, Meniere disease, syphilis, and presbycusis. Presurgical and postsurgical findings are included. The section on the basic hearing evaluation defines the terms employed and outlines the procedures to be used in
Frontiers in Pharmacology · 2024 · 1 citations · open access
Editorial: Identifying novel drug delivery systems and treatments for hearing loss and related ear disorders, volume II
AbstractEditorial on the Research Topic Identifying novel drug delivery systems and treatments for hearing loss and related ear disorders, volume II Development of drug delivery system (DDS) for the middle ear is a useful way to treat otitis media, which is still a very common disease.Furthermore, the development of DDS for the inner ear is a very important, as is drug development for the inner ear.No matter how good a drug is, if it does not reach the inner ear, it has no clinical significance.On the other hand, even drugs with weak efficacy may be clinically effective if they reach the inner ear in large doses.Most therapeutic drugs are administered orally or by injection, but the inner ear contains blood labyrinth barriers (BLBs), which are often difficult to reach by administration through the blood.Local administration or intratympanic injection (ITI) of drug to the inner ear is therefore considered, but the inner ear is anatomically surrounded by bone and has a barrier in the inner ear membrane.Additionally, because administering drugs through a hole in the inner ear membrane can cause mechanical damage, we also consider whether the drug can penetrate the barrier.Furthermore, we administer the drug slowly over a long period because the volume of inner ear is very small.In this Research Topic, we have six following articles addressing the above issues.1) Two articles discussing methods of inner ear administration, 2) two articles on intratympanic steroid administration, which is currently used in clinical practice, and 3) two articles attempting to improve age-related hearing loss (ARHL) or presbycusis (Figure 1).The novel developments in drug delivery for middle and inner ear administration including novel controlled release therapeutics such as hydrogel and nanotechnology and finally, novel device delivery approaches such as microfluidic systems and cochlear prosthesis-mediated delivery (Delaney et al.).Because the size of the inner ear differs between humans and other animals, it is questionable whether the results of nonclinical studies can be applied to humans, however, pharmacokinetics in catheterized piglets were evaluated using fluorescent dyes.Fluorescent
The Journal of the Acoustical Society of America · 1979 · 0 citations
Medical management of hearing disorders
AbstractThe auditory system consists of an outer, middle, and inner ear, the auditory nerve, and central auditory pathways. Each area has specific functions and each has diseases that impair that function. The purpose of this discussion is to present some of the more common diseases that afflict the auditory system and to discuss current techniques in diagnosis, medical/surgical treatment and unsolved problems that require continued research efforts.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
